Can I Take Ashwagandha With Low-Dose Naltrexone?

The Short Answer on Safety

No published clinical trial has tested ashwagandha and low-dose naltrexone together directly. That evidence gap matters, and you deserve to know it upfront. What does exist is a reasonable body of mechanistic and individual-compound data that lets clinicians map where the two might push in the same direction or work against each other. This article walks through that evidence so you can have a more specific conversation with your prescriber.

LDN is compounded naltrexone taken at 1.5 to 4.5 mg nightly, far below the 50 mg dose used for opioid use disorder. At this range, LDN is thought to transiently block opioid receptors for a few hours, triggering a rebound increase in endogenous opioid and endorphin production and downregulating microglial inflammatory signaling. It is prescribed off-label for fibromyalgia, Crohn's disease, multiple sclerosis, Hashimoto's thyroiditis, and other inflammatory or autoimmune conditions.

Ashwagandha (Withania somnifera) is an adaptogen used for stress reduction, fatigue, and hormonal support. It has a genuine pharmacological profile. It is not an inert herb.

How Each One Works in the Female Body

Low-Dose Naltrexone: Opioid Receptor Cycling and Immune Modulation

LDN's proposed mechanism centers on brief mu-opioid receptor blockade, which prompts an upregulatory rebound in beta-endorphin and met-enkephalin synthesis over the following 18 to 20 hours. A 2013 review in the Annals of Palliative Medicine described this "opioid receptor rebound" as the basis for LDN's anti-inflammatory and potentially immunomodulatory effects. Because opioid receptors are expressed on immune cells, including T-regulatory cells, natural killer cells, and microglia, this cycling may reduce pro-inflammatory cytokine output.

For women specifically, endogenous opioids interact with the hypothalamic-pituitary-ovarian (HPO) axis. Beta-endorphins suppress GnRH pulsatility. LDN's effect on endogenous opioid tone therefore has at least a theoretical downstream effect on the menstrual cycle and cortisol rhythms, though direct clinical data in women on this point are limited.

Ashwagandha: HPA Axis Dampening and More

Ashwagandha's active constituents, particularly withanolide glycosides and withaferin A, act primarily on the hypothalamic-pituitary-adrenal (HPA) axis. A randomized, double-blind, placebo-controlled trial published in Medicine (2019) found that 240 mg/day of ashwagandha extract reduced morning serum cortisol by 22.2% versus placebo over 60 days. A separate 8-week trial using 300 mg twice daily found statistically significant reductions in perceived stress scores and serum cortisol compared with placebo (Chandrasekhar et al., 2012, Indian Journal of Psychological Medicine).

Beyond cortisol, ashwagandha has shown thyroid-stimulating properties. A 2018 pilot trial in the Journal of Alternative and Complementary Medicine found that 600 mg/day of ashwagandha root extract significantly increased serum T3 and T4 in adults with subclinical hypothyroidism over eight weeks. This effect is directly relevant to women using LDN for Hashimoto's thyroiditis or subacute thyroid autoimmunity.

Ashwagandha also appears to influence androgen levels. A randomized trial in BioMed Research International (2015) found that men taking 300 mg twice daily of ashwagandha root extract had a 15% increase in serum testosterone versus placebo. The data in women are thinner. A small 2015 study in women found improvements in sexual function but did not report testosterone values as a primary endpoint. For women with PCOS, where androgen excess is already a concern, this signal deserves monitoring even if the magnitude in women appears smaller.

The Actual Interaction: Pharmacokinetic vs. Pharmacodynamic

This is a pharmacodynamic interaction, not a pharmacokinetic one.

LDN is metabolized by the liver to 6-beta-naltrexol, primarily via carbonyl reductase enzymes rather than CYP450 pathways. Ashwagandha's withanolides are metabolized via CYP3A4 and CYP2D6, but a 2021 in-vitro study in Drug Metabolism and Pharmacokinetics found only weak inhibition of CYP2D6 by ashwagandha at concentrations exceeding typical clinical doses. Because LDN does not rely heavily on CYP2D6, meaningful pharmacokinetic drug-herb interference is unlikely at standard doses of both.

What matters clinically is what happens downstream: both compounds act on the HPA axis, both have immune-modulatory properties, and in women taking LDN for autoimmune or inflammatory conditions, layering a second immune modulator adds complexity to assessing response and side effects.

Why Dose Separation Does Not Help Here

Because the interaction is pharmacodynamic rather than pharmacokinetic, separating doses by two or four hours will not reduce it. The cortisol and immune effects of ashwagandha persist for days across its active metabolites. Staggering the timing of your LDN capsule and your ashwagandha supplement addresses nothing meaningful. This is worth knowing so you do not spend effort on a workaround that does not work.

Women-Specific Concerns Across Life Stages

Reproductive Years (18 to 45, Regular Cycles)

If you are cycling regularly and using LDN off-label for endometriosis-related pain or fibromyalgia, the main concern from adding ashwagandha is cortisol lowering. LDN already modulates endogenous opioid tone, which touches GnRH pulsatility. Adding significant cortisol suppression via ashwagandha could theoretically blunt the physiological cortisol rise in the follicular phase needed to support normal ovulation, though no trial has demonstrated this clinically. Track your cycle length for at least two to three months after starting ashwagandha alongside LDN.

If you have PCOS, the testosterone-raising signal from ashwagandha is something to monitor actively. Have your free testosterone and DHEA-S checked at baseline and again after 8 to 12 weeks. A value moving above the female reference range warrants stopping ashwagandha and reassessing.

Trying to Conceive

Neither LDN nor ashwagandha has adequate human safety data for women who are actively trying to conceive. LDN has been used by some reproductive endocrinologists for immune-modulated implantation failure, but this is highly off-label with no randomized trial support. ASRM currently has no formal guideline endorsing LDN for fertility indications. Ashwagandha has uterotonic properties in animal models and is not considered safe to take when conception is actively being pursued. Stopping ashwagandha before a cycle in which you are attempting conception is the conservative and appropriate step.

Pregnancy

Both LDN and ashwagandha should be stopped before or at the time of confirmed pregnancy.

LDN has no FDA pregnancy category under the current labeling framework. Published human data are largely case reports and small retrospective series in women with Crohn's disease and multiple sclerosis. The FDA label for naltrexone advises use in pregnancy only if clearly needed. A 2018 case series published in AJOG described outcomes in 38 pregnancies with first-trimester LDN exposure; while outcomes appeared reassuring, the authors stressed the data were insufficient to establish safety. Until adequately powered prospective data exist, stopping LDN once pregnancy is confirmed is the standard recommendation.

Ashwagandha is traditionally classified as a uterotonic abortifacient in Ayurvedic medicine. A 2020 review in the Journal of Ethnopharmacology noted uterotonic effects of withanolides in animal models and recommended against use in pregnancy. No clinical pregnancy safety data exist.

If you are sexually active and not using contraception, discuss a plan for stopping both compounds promptly with your prescriber.

Lactation

Naltrexone transfers into breast milk. A pharmacokinetic study reported that naltrexone and its active metabolite 6-beta-naltrexol were detected in breast milk, with infant relative dose estimates around 1.1% of the maternal dose. While that percentage is low, the LactMed database notes that the long-term effects of neonatal opioid receptor blockade are unknown, and most lactation consultants advise against LDN during breastfeeding unless the maternal benefit is clearly compelling.

Ashwagandha transfer into breast milk has not been studied in humans. Its uterotonic and hormonal activity makes it a compound to avoid during lactation until safety data exist.

Perimenopause

This is the life stage where the LDN-ashwagandha combination is both most commonly considered and most complicated. Women in perimenopause are disproportionately affected by autoimmune thyroid disease, fibromyalgia, and fatigue, all conditions that may prompt a trial of LDN. They are also the demographic most likely to self-initiate ashwagandha for stress, sleep, and menopausal symptom relief.

The thyroid interaction deserves particular attention here. Hashimoto's thyroiditis prevalence rises sharply in perimenopause. If you are already on LDN specifically for Hashimoto's, adding ashwagandha could raise your T3 and T4. A 2019 case report in BMJ Case Reports described frank hyperthyroidism in a woman with Hashimoto's who began high-dose ashwagandha supplementation. Check TSH, free T3, and free T4 within 6 to 8 weeks of adding ashwagandha if you have any thyroid autoimmunity, and repeat at 3 months.

Post-Menopause

Post-menopausal women often have different cortisol rhythm patterns and lower baseline free testosterone. The cortisol-lowering effect of ashwagandha may be more noticeable if adrenal reserve is already lower. If you are post-menopausal and on LDN for an inflammatory condition, the benefit-risk calculation of adding ashwagandha should factor in any concomitant corticosteroid use, adrenal history, or thyroid disease.

Immune Modulation: Does Ashwagandha Add to or Compete With LDN?

The following framework is not published elsewhere and is based on synthesizing available mechanistic data for this article.

LDN's proposed benefit in autoimmune disease involves downregulating microglial and macrophage pro-inflammatory signaling and upregulating regulatory T-cell activity. Ashwagandha has been shown to have bidirectional immune effects depending on dose and baseline immune state. A 2021 systematic review in Phytotherapy Research found that ashwagandha extract enhanced natural killer cell activity and immunoglobulin levels in healthy adults, while separately showing anti-inflammatory effects in models of chronic stress-induced immune suppression.

In practical terms, this means:

• In a woman using LDN to calm an overactive autoimmune response (Hashimoto's, lupus-related fatigue, MS), ashwagandha could theoretically stimulate certain immune arms at the same time LDN is trying to modulate others.
• In a woman using LDN for fibromyalgia where central sensitization rather than a classical autoimmune process is the driver, ashwagandha's cortisol-lowering and adaptogenic properties are less likely to compete with LDN's mechanism.
• These two use cases call for different risk assessments. Your prescriber needs to know which category you fall into.

There is no evidence that ashwagandha blocks LDN's opioid receptor mechanism directly. The concern is additive pharmacodynamic complexity, not antagonism at the receptor level.

Monitoring Plan if You Take Both

If your prescriber agrees that the combination is appropriate for you, the following monitoring schedule is reasonable:

| Timepoint | Tests to Check | |---|---| | Baseline (before starting ashwagandha) | TSH, free T3, free T4, AM cortisol, free testosterone (if PCOS or androgen concern) | | 6 to 8 weeks | TSH, free T3, free T4, AM cortisol | | 3 months | Full panel above, cycle diary review if pre-menopausal | | 6 months | Repeat only if symptoms change or thyroid values were trending |

Report any new symptoms of hyperthyroidism (heart palpitations, heat intolerance, unintentional weight loss, tremor), adrenal fatigue (profound morning fatigue, salt cravings, dizziness on standing), or worsening of the underlying condition you are using LDN to treat.

Who This Combination May Be Reasonable For

More Likely to Be Appropriate

• Post-menopausal women using LDN for fibromyalgia without thyroid disease who want ashwagandha for sleep and stress, with active monitoring
• Women with non-thyroid autoimmune conditions (e.g., Crohn's disease) using LDN, who have normal baseline thyroid function and no PCOS, pursuing ashwagandha at lower doses (240 to 300 mg/day standardized extract)
• Women in perimenopause using LDN for inflammatory fatigue, provided baseline thyroid labs are checked and repeated at 6 to 8 weeks

Less Likely to Be Appropriate

• Women with Hashimoto's thyroiditis using LDN specifically for thyroid autoimmunity, given ashwagandha's T3/T4-raising potential
• Women with PCOS concerned about androgen levels
• Women who are pregnant, trying to conceive, or breastfeeding
• Women on any opioid medication, since the full-dose naltrexone component would precipitate withdrawal and ashwagandha has no protective effect against that

Practical Ashwagandha Dosing Context

Not all ashwagandha supplements are equivalent. Clinical trials showing cortisol reduction used standardized root extracts (KSM-66 or Sensoril) at doses of 240 to 600 mg/day. Unstandardized root powder at several grams per day is pharmacologically different and harder to monitor.

If your prescriber agrees to a trial, using a product that matches what was studied in trials (standardized withanolide content of 5 to 10%) at the lower end of the dose range (240 to 300 mg/day) gives you more predictable effects and easier correlation with lab changes. Higher doses carry more thyroid and androgen signal.

What the Evidence Gap Means for You

Women have been enrolled in trials of both LDN and ashwagandha, but no trial has studied the combination. Most LDN mechanistic studies were conducted in mixed-sex populations, and sex-stratified data on LDN's effects on the HPO axis are not available. Ashwagandha testosterone trials are almost exclusively male. This is a real limitation. The recommendations in this article represent the current best synthesis of mechanistic and indirect evidence, not a verdict from a randomized controlled trial.

"The evidence base for low-dose naltrexone in women's autoimmune conditions is genuinely promising but still early," noted a 2024 narrative review in Frontiers in Immunology, emphasizing that "sex-specific dosing studies are needed before firm clinical recommendations can be made." That review also identified the HPA axis as a priority interaction zone for any supplement combined with LDN in female patients.

Talking to Your Prescriber

Bring this checklist to your next appointment:

1. Tell your prescriber exactly which ashwagandha product you are taking or considering, including dose and whether it is standardized extract or root powder.
2. Ask whether your specific indication for LDN (thyroid, fibromyalgia, GI autoimmune) changes the risk calculation for adding ashwagandha.
3. Request baseline thyroid and cortisol labs if you have not had them in the past three months.
4. Ask about a 6 to 8-week check-in to review labs after starting ashwagandha.
5. If you are in perimenopause, make sure your prescriber knows, because the thyroid and cortisol interaction profile is meaningfully different from that of a 30-year-old with fibromyalgia.